Recent news on Peginterferon

Possible Hepatitis C Cure Announced  -  25 May 2007
About - News & Issues,Results have been announced for a long-term follow-up study designed to monitor for recurrence of Hepatitis C in patients treated with peginterferon

Peginterferon May Cure Hepatitis C  -  May 22, 2007
Dog Flu Diet and Diseases,In the study, 997 people with hepatitis C were treated with either peginterferon, or peginterferon and ribavirin. Over an extensive follow up period,

Celgosivir with Peginterferon and Ribavirin in Chronic Hepatitis C  -  May 21, 2007
SpiritIndia,Non-responder patient study results also demonstrate an improved mean decrease in HCV viral loads when celgosivir is added to peginterferon alfa-2b and

Retrospective Analysis of the Effect of Taking a Statin Along with ...  -  May 21, 2007
SpiritIndia,Researchers retrospectively analyzed the effect of taking peginterferon and ribavirin (PI+R, hepatitis C treatment options) and PI+R plus a statin to

Cure for Hepatitis C found  -  May 22, 2007
DailyIndia.com,Washington, May 22: Researchers at the Virginia Commonwealth University Medical Center say that peginterferon alfa therapy harbours the cure for chronic

Researchers Claims to Have Found Cure for Hepatitis C  -  May 22, 2007
MedIndia,Researchers at the Virginia Commonwealth University Medical Center say that peginterferon alfa therapy harbors the cure for chronic hepatitis C.

Study Suggests Cure for Hepatitis C  -  May 21, 2007
Atlanta Journal Constitution (subscription),Use of the drug peginterferon, either alone or in combination with the drug ribavirin, reduced levels of the virus to undetectable levels for up to seven

Cure for hepatitis C announced  -  May 22, 2007
HULIQ,The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the

Researchers find cure for hepatitis C  -  May 21, 2007
South Asian Women's Forum,22 May 2007 (Sawf News) - The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis

Approvals: Herceptin, Reyataz, and Peg-Intron  -  May 21, 2007
Medscape (subscription)On April 5, the Chinese State Food and Drug Administration approved a new indication for peginterferon alfa-2b injection (Peg-Intron, Schering-Plough

Cure For Hepatitis C Announced By Researcher  -  May 21, 2007
Science Daily (press release)Science Daily — The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis,

Cure for Hepatitis C Announced  -  May 21, 2007
Newswise (press release)Newswise — The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer

Cure for hepatitis C announced by VCU researcher  -  May 21, 2007
EurekAlert (press release),...(May 21, 2007) – The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis,

DRUG CURE FOR HEP C  -  May 22, 2007
Mirror.co.uk,The use of peginterferon and ribavirin could save thousands of lives. Research on 1000 patients was carried out at the Virginia Commonwealth University

Cure for Hep C?  -  May 21, 2007
Ivanhoe,New research from Virginia Commonwealth University shows 99 percent of hepatitis C patients who were treated successfully with peginterferon alone,

Data Suggest that PEGASYS® May be an Option in Hepatitis C ...  -  May 21, 2007
WebWire (press release),Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron® (peginterferon alfa-2b) and

DDW: Contrary to Common Wisdom, Statins May Offer Liver Benefit  -  May 20, 2007
MedPage Today,And data from the VA's HCV database hint that when statins are given to patients who are receiving standard HCV therapy with peginterferon and ribavirin,

'65% of syringes used in India are unsafe'  -  May 22, 2007
Hindustan Times,A medical process called peginterferon alfa therapy has had 99 % success in completely curing the fatal viral disease. "Sixty five per cent of syringes used

Schering-Plough Announces Hepatitis C Data Presentations at ...  -  May 18, 2007
PR Newswire (press release),REBETOL in patients chronically infected with HCV genotype 1 who were null responders to previous peginterferon and ribavirin combination therapy (ie,

Meeting Highlights From The Committee For Medicinal Products For ...  -  Apr 27, 2007
Medical News Today (press release),Pegintron and Viraferonpeg (peginterferon alfa-2b), from Schering Plough Europe, to extend the indication of these medicines to include the treatment of

Schering-Plough Announces Hepatitis C Data Presentations At ...  -  May 19, 2007
Medical News Today (press release),A total of 20 oral and poster presentations on clinical studies with Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b)

Data Suggest that PEGASYS(R) May be an Option in Hepatitis C ...  -  May 21, 2007
Genetic Engineering News (press release),Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron(R) (peginterferon alfa-2b) and

Data Suggest that PEGASYS ® May be an Option in Hepatitis C ...  -  May 21, 2007
Business Wire (press release),...that all patients who discontinued treatment with Peg-Intron ® (peginterferon alfa-2b) and ribavirin due to adverse events within the first 12 weeks,

PEGASYS® Study Authors Conclude that Patients Successfully Treated ...  -  May 22, 2007
WebWire (press release),...showed that more than 99 percent of patients with chronic hepatitis C virus (HCV) infection who were treated successfully with PEGASYS® (peginterferon

Hepatitis C breakthrough may save lives  -  May 22, 2007
Hindustan Times,A medical process called peginterferon alfa therapy has had 99 % success in completely curing the fatal viral disease. Indo-Asian News Service, PTI

Pegasys Study Authors Conclude that Patients Successfully Treated ...  -  May 21, 2007
PharmaLive.com (press release),...showed that more than 99 percent of patients with chronic hepatitis C virus (HCV) infection who were treated successfully with PEGASYS(R) (peginterferon

PEGASYS ® Study Authors Conclude that Patients Successfully ...  -  May 21, 2007
Business Wire (press release),...showed that more than 99 percent of patients with chronic hepatitis C virus (HCV) infection who were treated successfully with PEGASYS ® (peginterferon

Statins may help treat hepatitis C  -  May 21, 2007
Times of India,As part of naother study researchers retrospectively analyzed the effect of taking peginterferon and ribavirin (PI+R, hepatitis C treatment options) and

MIGENIX to Present Celgosivir Phase II Hepatitis C Results at ...  -  May 18, 2007
CNW Telbec (Communiqués de presse),The presentation entitled: "Phase II Study of Celgosivir in Combination with Peginterferon alfa-2b and Ribavirin in Chronic Hepatitis C Genotype-1

European Union's CHMP Issues Positive Opinion On PEGINTRON(Tm) And ...  -  May 1, 2007
Medical News Today (press release),European Medicines Agency (EMEA) has issued a positive opinion recommending approval of combination therapy with PEGINTRON(TM) (peginterferon alfa-2b,

Roche updates on flu manufacturing; expands US unit  -  26 Apr 2007
In-PharmaTechnologist.com,...including cancer drug Xeloda (capecitabine), Pegasys (peginterferon alfa-2a) for hepatitis, Tamiflu and Xenical (orlistat) for obesity.

Telaprevir Plus Peginterferon Alfa-2a and Ribavirin Drives 79% of ...  -  Apr 16, 2007
DG News...[Presentation Title: Results of an Interim Analysis of a Phase 2 Study of Telaprevir (VX-950) With Peginterferon alfa-2a and Ribavirin in Previously

Hepatitis C Patients With Advanced Kidney Disease Benefit From ...  -  Apr 16, 2007
DG NewsResults at 12 weeks showed that in patients receiving peginterferon alfa-2a 135 mcg/week, there were significantly more virological responders at week 12

Psychiatric Disorders No Reason to Exclude Hepatitis C Patients ...  -  Apr 16, 2007
DG NewsBARCELONA, SPAIN -- April 16, 2007 -- A history of psychiatric disorders should not be a contraindication to treatment with peginterferon-alfa2b plus

New Clinical Study Results Indicate Higher Early Virologic ...  -  Apr 11, 2007
CNW Telbec (Communiqués de presse),The presentation entitled: "Phase II Proof of Concept Study of Celgosivir in Combination with Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C

Sustained Response to Anti-Hepatitis C Virus Drugs Results in Cure ...  -  Apr 16, 2007
DG NewsOf patients who achieved a SVR, 163 patients who had HCV monoinfection were treated with peginterferon alfa-2a alone; 741 patients with HCV monoinfection

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Apr 6, 2007
Drug Newswire (press release),Over 1000 patients will be enrolled into PROGRESS and these patients will be randomized to receive one of four dosing regimens of peginterferon alfa-2a

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
Juraforum.de,Patients with genotype1 hepatitis C (HCV) who clear the virus within a month of startingtreatment with PEGASYS (peginterferon alfa-2a (40KD)) plus

Higher Doses of Ribavirin Are Effective in Hepatitis C Virus ...  -  Apr 13, 2007
DG News...[Presentation title: Management of Chronic Hepatitis C in a Diverse Population With Peginterferon Alfa-2A and Ribavirin: Final Results of the Canadian

Schering-Plough Wins Chinese Approval For PEGINTRON For Treatment ...  -  Apr 5, 2007
Trading Markets,...(SGP | charts | news | PowerRating) revealed that PEGINTRON or peginterferon alfa-2b has been approved by the Chinese State Food and Drug Administration for

EASL: Telaprevir Shows Promise of Shortened Hepatitis C Therapy  -  Apr 16, 2007
MedPage Today,Another 80 patients treated with telaprevir for 12 weeks in addition to the other drugs. Peginterferon plus ribavirin continued for another 36 weeks.

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
campus med,Patients with genotype 1 hepatitis C (HCV) who clear the virus within a month of starting treatment with PEGASYS (peginterferon alfa-2a (40KD)) plus COPEGUS

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 11, 2007
PR Newswire (press release),Peginterferon Alfa-2b and Ribavirin for 14 or 24 Weeks in Patients with HCV Genotype 2 or 3 and Rapid Virological Response, The North-C Trial.

Vertex Pharmaceuticals Announces New Data for Investigational HCV ...  -  Apr 11, 2007
PharmaLive.com (press release),A late-breaker presentation titled, "Results of an Interim Analysis of a Phase 2 Study of Telaprevir (VX-950) with Peginterferon alfa-2a and Ribavirin in

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 10, 2007
PR Newswire (press release),Key Data Presentations at EASL PEGINTRON Peginterferon Alfa-2b and Ribavirin for 14 or 24 Weeks in Patients with HCV Genotype 2 or 3 and Rapid Virological

Human Genome Sciences reports results of phase 2b trial of Albuferon  -  Apr 17, 2007
News-Medical.net,..."The interim data presented at EASL suggest that Albuferon may offer efficacy at least comparable to peginterferon alfa-2a, with half the injections and the

Human Genome Sciences Reports Positive Interim Results of Phase 2b ...  -  Apr 14, 2007
PR-Inside.com (Pressemitteilung),Albuferon may offer efficacy at least comparable to peginterferon alfa-2a, with half the injections and the potential for less impairment of quality of life

Analysis: Total hepatitis C cure possible  -  Apr 12, 2007
Science Daily (press release)Of the patients who did achieve a sustained virologic response, 163 patients who only had hepatitis C infections were treated with peginterferon alfa-2a

EASL: Sustained Virologic Response Equals Cure for HCV Infection  -  Apr 12, 2007
MedPage Today,Of the patients who achieved a sustained virologic response, 163 who only had HCV infections were treated with peginterferon alfa-2a monotherapy;

Milestones, Challenges In Treatment Of Patients With Chronic ...  -  Apr 11, 2007
eMaxHealth.com,Among these are several studies with PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin) combination therapy, a current standard of care in the

In vitro results support expansion of telaprevir clinical ...  -  Apr 11, 2007
Business Wire (press release),A late-breaker presentation titled, “Results of an Interim Analysis of a Phase 2 Study of Telaprevir (VX-950) with Peginterferon alfa-2a and Ribavirin in

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PR Newswire (press release),2 Manns, M. Peginterferon Alfa-2b Plus Ribavirin Compared with Interferon Alfa-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C: A Randomized

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PharmaLive.com (press release),Hepatitis C Virus Infection. New England Journal of Medicine 2002. 2 Manns, M. Peginterferon Alfa-2b Plus Ribavirin Compared with Interferon.

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Apr 6, 2007
Drug Newswire (press release),Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

MIGENIX Reports Third Quarter Fiscal Year 2007 Financial Results  -  Apr 4, 2007
Drug Newswire (press release),...using celgosivir triple combination (celgosivir plus peginterferon alfa-2b plus ribavirin) as compared to the active control treatment (peginterferon

SP delivers again, beating forecasts  -  Apr 20, 2007
Pharma Times (subscription),Among other products boosting revenue was the antibiotic Avelox (moxifloxacin), up 43% to $115 million, and Pegintron (peginterferon alfa-2b) for hepatitis

Vertex to meet hepatitis C patients' needs?  -  Apr 17, 2007
LabTechnologist.com,...with Roche's pegylated interferon Pegasys (peginterferon alfa-2a; peg-IFN) and ribavirin (RBV) enabled some patients to clear the virus in 12 weeks.

Schering-Plough commits to chronic hepatitis C research  -  Apr 12, 2007
News-Medical.net,Among these are several studies with PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin) combination therapy, a current standard of care in the

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),...(Announced April 4) -- Gained approval from the Chinese State Food and Drug Administration for PEGINTRON (peginterferon alfa-2b) for the treatment of

MIGENIX Receives New Clinical Study Results Indicating Higher ...  -  Apr 11, 2007
Trading Markets,...over 12 weeks of treatment, the efficacy, safety, and tolerability of celgosivir in combination with peginterferon alfa-2b, with or without ribavirin,

PEGINTRON(TM) Approved In China For Treating Chronic Hepatitis B  -  Apr 8, 2007
Medical News Today (press release),Schering-Plough Corporation (NYSE: SGP) today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been approved by the Chinese State Food and Drug

Biotech In Review: Bidding War Erupts For Biosite  -  Apr 7, 2007
Seeking Alpha,There are 120 million chronic carriers of the disease and 330000 deaths annually, due to complications from hepatitis B. Pegintron, or peginterferon alfa-2b

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 6, 2007
Drug Newswire (press release),KENILWORTH, NJ, April 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
PR Newswire (press release),KENILWORTH, NJ, April 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that PEGINTRON(TM) (peginterferon alfa-2b) has

SFDA Approves Schering-Plough's Pegintron For Chronic Hepatitis B ...  -  Apr 5, 2007
Trading Markets,State Food and Drug Administration or SFDA has approved its Pegintron or peginterferon alfa-2b for the treatment of patients with chronic hepatitis B.

Pegintron Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
PharmaLive.com (press release),KENILWORTH, NJ, April 05, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
PR-Inside.com (Pressemitteilung),KENILWORTH, NJ, April 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been approved

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
Earthtimes.orgKENILWORTH, NJ, April 5 -- Schering-Plough Corporation today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been approved by the Chinese State

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
PR Newswire (press release),April 5 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that PEGINTRON(TM) (peginterferon alfa-2b) has been approved

Singapore growing biopharma strength  -  Apr 2, 2007
DrugResearcher.com,The Singaporean sites manufacture Schering's hepatitis C treatment Peg-Intron (peginterferon alpha-2b) and Remicade (infliximab) for Crohn's disease and

Roche starts PROGRESS trial in Poland  -  Mar 21, 2007
Polish Market,The international study will evaluate the effect of Pegasys (peginterferon alfa-2a (40KD)) and Copegus (ribavirin) in hepatitis C patients who have a high

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
PR-Inside.com (Pressemitteilung),Over 1000 patients will be enrolled into PROGRESS and these patients will be randomized to receive one of four dosing regimens of peginterferon alfa-2a

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
news aktuell (Pressemitteilung),The four dosing regimens are: Arm 1 - A fixed-dose induction (360 mg) of peginterferon alfa-2a (40KD) given once every week for the first 12 weeks,

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
Earthtimes.orgArm 1 - A fixed-dose induction (360 mg) of peginterferon alfa-2a (40KD) given once every week for the first 12 weeks, then the standard licensed 180 microg

MIGENIX Reports Third Quarter Fiscal Year 2007 Financial Results  -  Mar 13, 2007
CNW Telbec (Communiqués de presse),...using celgosivir triple combination (celgosivir plus peginterferon alfa-2b plus ribavirin) as compared to the active control treatment (peginterferon

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Mar 5, 2007
PR Newswire UK (press release),Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Mar 5, 2007
Earthtimes.orgPeginterferon-alpha2aand ribavirin combination therapy in chronic hepatitis C: a randomized studyof treatment duration and ribavirin dose.

Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study  -  Mar 15, 2007
PharmaLive.com (press release),..."The development of this antiviral compound could be of great benefit due to its potential to reduce the anemia seen with conventional peginterferon and

Roche Driving PROGRESS in Treatment of Hepatitis C  -  Mar 14, 2007
WebWire (press release),This study will evaluate the effect of PEGASYS® (peginterferon alfa-2a) and ribavirin in patients who have a high level of genotype 1 virus in their blood

IDM Pharma Announces the Completion of Enrollment in Two Phase II ...  -  Mar 1, 2007
PipelineReview.com (press release),...tumor antigens following treatment with Uvidem, administered with or without peginterferon alpha-2b in patients with resected stage II or III melanoma.

Human Genome Sciences Announces Positive Interim Results of Phase ...  -  Feb 28, 2007
PharmaLive.com (press release),The fourth treatment group serves as the active control group and received 180-mcg doses of subcutaneously administered peginterferon alfa-2a (Pegasys) once

Human Genome Sciences Initiates Phase 3 Clinical Trial of ...  -  Feb 28, 2007
PharmaLive.com (press release),...on health-related quality of life of Albuferon in combination with ribavirin, versus PEGASYS (peginterferon alfa-2a) in combination with ribavirin.

Hepatitis C Treatment Center  -  Feb 6, 2007
WebMDPEGASYS (Peginterferon alfa-2a), like other alpha interferons, can cause fatal or make life-threatening problems worse (like mental, immune system, heart,

Cancer Research chief questions firms' clinical study set-up  -  Jan 31, 2007
Pharma Times (subscription),...period of use reduced, pointing to an on-going study into halving the period of use for its hepatitis C drug Pegasys (peginterferon alfa-2a).

Hepatitis C  -  Feb 20, 2007
Journal of American Medical Association (subscription),Peginterferon combined with ribavirin are the 2 antiviral drugs now being used. Side effects of drug treatment can be serious, and your doctor may suggest

Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines  -  Feb 7, 2007
New England Journal of Medicine (subscription),...government has granted only one patent on a pharmaceutical product — to Hoffmann–La Roche, for its hepatitis C therapy, peginterferon alfa-2a (Pegasys).

MIGENIX provides update on license-option agreement with Schering ...  -  Feb 6, 2007
CNW Telbec (Communiqués de presse),Material Transfer and License Option Agreement Under the terms of the Agreement, Schering supplied PEGETRON(TM) (peginterferon alfa-2b powder for solution

Migenix hepatitis study samples require retesting  -  Feb 6, 2007
Pharmaceutical Business ReviewSchering-Plough was supplying Pegetron (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as other services for the trial as

Migenix Provides Update on License-Option Agreement with Schering ...  -  Feb 6, 2007
PharmaLive.com (press release),Under the terms of the Agreement, Schering supplied PEGETRON(TM) (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as

Schering-Plough's turnaround is moving on apace  -  Jan 30, 2007
Pharma Times (subscription),Brain cancer treatment Temodar enjoyed a sales rise of 18% to $189 million, but Peg-Intron (peginterferon alfa) fell 3% to $208 million, hampered by a

Copegus Approved In Japan As Combination Therapy With Pegasys For ...  -  Jan 29, 2007
Medical News Today (press release),Roche and Chugai announced today that the combination of Copegus (ribavirin) plus Pegasys (peginterferon alfa-2a (40KD)) has been approved in Japan

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),Despite an overall decline in market volume in the US and competition from a combination treatment in Japan, sales of Pegasys (peginterferon alfa-2a),

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional